|
| PARP inhibitors | Tumor types | Most advanced developmental stage in progress | Key clinical trials | References |
|
| Olaparib | FDA approved for ovarian cancer
Being tested for breast, prostate, and pancreatic cancers | FDA approved | Phase II trial found that Olaparib monotherapy in patients with BRCA1/2 mutated ovarian cancer following ≥3 chemotherapy treatments resulted in 31% response rate
Phase II trial found that Olaparib maintenance therapy in patients with platinum- (Pt-) sensitive recurrent serous ovarian cancer with mutated BRCA1/2 resulted in median progression free survival of 6.9 months longer than those receiving placebo | [150, 151] |
|
| Talazoparib | Being tested for ovarian, breast, and various advanced/metastatic solid cancers (primary peritoneal carcinoma, fallopian tube carcinoma, etc.) | Phase III | Phase II trial for Talazoparib monotherapy in patients with deleterious BRCA1/2 mutated ovarian cancer who had prior PARP inhibitor treatment currently recruiting
Phase III trial for Talazoparib monotherapy in patients with BRCA1/2 mutated, advanced, or metastatic breast cancer currently recruiting | [152, 153] |
|
| Veliparib | Being tested for breast, pancreatic, non-small-cell lung cancers, lymphoma, and multiple myeloma, mostly in combination with chemotherapy | Phase III | Phase I/II trial of Veliparib and Topotecan for relapsed ovarian cancer of negative or unknown BRCA status completed
Phase II trial of Veliparib alone or with Gemcitabine and Cisplatin in patients with locally advanced or metastatic pancreatic cancer currently recruiting
Phase I/II trial for Veliparib, Bendamustine HCl, and Rituximab in patients with relapsed lymphoma and multiple myeloma completed | [154–156] |
|
| Rucaparib | Being tested for ovarian and pancreatic cancers | Phase III | Phase III trial for Rucaparib maintenance therapy in patients with Pt-sensitive recurrent ovarian cancer, fallopian tube, or primary peritoneal cancers currently recruiting
Phase II trial for Rucaparib monotherapy in patients with BRCA1/2 mutated, locally advanced, or metastatic pancreatic cancer currently ongoing | [157, 158] |
|
| Niraparib | Being tested for ovarian and breast cancers and Ewing sarcoma | Phase III | Phase III trial for Niraparib monotherapy in patients with HER2 negative, BRCA1/2 mutated breast cancer currently recruiting
Phase II trial for Niraparib monotherapy in patients with ovarian cancer following ≥3 chemotherapy treatments currently recruiting | [159–161] |
|
